false 0001752828 0001752828 2024-12-19 2024-12-19 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2024-12-19 2024-12-19 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2024-12-19 2024-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 19, 2024

 

 

 

Celularity Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38914   83-1702591
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
         
170 Park Ave    
Florham Park, New Jersey       07932
(Address of principal executive offices)       (Zip Code)

 

Registrant’s telephone number, including area code: (908) 768-2170

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share   CELU   The Nasdaq Stock Market LLC
Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per share   CELUW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 19, 2024, Celularity Inc., or Celularity, held its Annual Meeting of Stockholders, or the Annual Meeting. At the Annual Meeting, Celularity’s stockholders voted on two proposals, each of which is described in more detail in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on November 19, 2024. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

 

Proposal 1. Stockholders elected the following nominee to serve as the Class III Director on Celularity’s Board of Directors until its 2027 Annual Meeting of Stockholders or until his respective successor has been duly elected and qualified or until his earlier death, resignation or removal. The voting results for the nominees were as follows:

 

Director Name   Votes For   Votes Withheld   Broker Non-Votes
Robert J. Hariri, M.D., Ph.D.   10,250,294   53,960   3,285,202

 

Proposal 2. Stockholders ratified the appointment of EisnerAmper LLP as Celularity’s independent registered public accounting firm for the fiscal year ending December 31, 2024 The voting results were as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
13,561,068   24,211   4,177   0

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CELULARITY INC.
       
Date: December 20, 2024 By: /s/ Robert J. Hariri
     

Robert J. Hariri, M.D., Ph.D.

Chairman and CEO